Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22991774 | 1.00 | ICAM1 (0.41) | ICAM1CYP3A4RECQLTDP1CYP1A2 | |
| SCHEMBL21475296 | 1.00 | ICAM1 (0.41) | ICAM1CYP3A4RECQLTDP1CYP1A2 | |
| SCHEMBL23008046 | 0.85 | ICAM1 (0.38) | ICAM1CYP3A4RECQLTDP1CYP1A2 | |
| SCHEMBL21479531 | 0.85 | ICAM1 (0.38) | ICAM1CYP3A4RECQLTDP1CYP1A2 | |
| SCHEMBL22991781 | 0.85 | ICAM1 (0.38) | ICAM1CYP3A4RECQLTDP1CYP1A2 | |
| SCHEMBL21479532 | 0.85 | ICAM1 (0.38) | ICAM1CYP3A4RECQLTDP1CYP1A2 | |
| SCHEMBL23007843 | 0.84 | ICAM1 (0.39) | ICAM1CYP3A4RECQLTDP1CYP1A2 | |
| SCHEMBL21479498 | 0.84 | ICAM1 (0.39) | ICAM1CYP3A4RECQLTDP1CYP1A2 | |
| SCHEMBL21479510 | 0.84 | ICAM1 (0.39) | ICAM1CYP3A4RECQLTDP1CYP1A2 | |
| SCHEMBL21475383 | 0.81 | ICAM1 (0.40) | ICAM1CYP3A4RECQLTDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047283-A1 | NOVEL LACTONE COMPOUND AND NOVEL ETHER COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2021-02-18 | — | — | US | disclosed |
| EP-3778581-A1 | NOVEL LACTONE COMPOUND AND NOVEL ETHER COMPOUND | Takasago International Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019198678-A1 | NOVEL LACTONE COMPOUND AND NOVEL ETHER COMPOUND | 高砂香料工業株式会社 | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047283-A1 | NOVEL LACTONE COMPOUND AND NOVEL ETHER COMPOUND | NR0B1, CBR1, DCXR | ICAM1 3353/4885CYP3A4 230/4885RECQL 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.